Literature DB >> 19668659

The crucial role of tumour specimen handling in childhood cancer outcomes.

Conrad V Fernandez1, Fergall Magee, Robert B Fraser.   

Abstract

The significant advances achieved in the care of children with cancer have been the result of carefully conducted clinical trials in international cooperative group settings. Specialized biological testing of tumour specimens is now an essential component of risk and treatment assignment for many childhood cancers. Thus, the appropriate collection and handling of tumour specimens is crucial to maintaining and further advancing the excellent outcomes that we have achieved. We recommend that all children with a strongly suspected malignancy, or cases in which the situation is unclear, be discussed with a paediatric oncologist before obtaining a tumour specimen. When a tumour is discovered incidentally at surgery, we recommend that the tumour be placed in a saline-soaked gauze and a paediatric pathologist or oncologist contacted immediately. Further progress in understanding and treating childhood cancer is intimately linked to basic studies of biology, translational research and determining the role of biological markers in risk stratification. Early and careful collaboration between front-line physicians and tertiary care oncology specialists is essential to the continuing success of treatment of children with cancer.

Entities:  

Keywords:  Paediatric cancer; Pathology

Year:  2005        PMID: 19668659      PMCID: PMC2722598     

Source DB:  PubMed          Journal:  Paediatr Child Health        ISSN: 1205-7088            Impact factor:   2.253


  16 in total

Review 1.  Pediatric cancer research from past successes through collaboration to future transdisciplinary research.

Authors:  Gregory H Reaman
Journal:  J Pediatr Oncol Nurs       Date:  2004 May-Jun       Impact factor: 1.636

2.  Clear cell sarcoma of the kidney: a review of 351 cases from the National Wilms Tumor Study Group Pathology Center.

Authors:  P Argani; E J Perlman; N E Breslow; N G Browning; D M Green; G J D'Angio; J B Beckwith
Journal:  Am J Surg Pathol       Date:  2000-01       Impact factor: 6.394

Review 3.  Update in childhood acute myeloid leukemia: recent developments in the molecular basis of disease and novel therapies.

Authors:  Jennifer J Clark; Franklin O Smith; Robert J Arceci
Journal:  Curr Opin Hematol       Date:  2003-01       Impact factor: 3.284

4.  Position statement for the need to define pediatric hematology/oncology programs: a model of subspecialty care for chronic childhood diseases. Health Care Policy and Public Issues Committee of the American Society of Pediatric Hematology/Oncology.

Authors:  R J Arceci; G H Reaman; A R Cohen; B C Lampkin
Journal:  J Pediatr Hematol Oncol       Date:  1998 Mar-Apr       Impact factor: 1.289

Review 5.  The U.S. pediatric cancer clinical trials programmes: international implications and the way forward.

Authors:  W A Bleyer
Journal:  Eur J Cancer       Date:  1997-08       Impact factor: 9.162

Review 6.  Advances in the diagnosis and treatment of neuroblastoma.

Authors:  Joanna L Weinstein; Howard M Katzenstein; Susan L Cohn
Journal:  Oncologist       Date:  2003

7.  Minimal residual disease detection in childhood precursor-B-cell acute lymphoblastic leukemia: relation to other risk factors. A Children's Oncology Group study.

Authors:  M J Borowitz; D J Pullen; J J Shuster; D Viswanatha; K Montgomery; C L Willman; B Camitta
Journal:  Leukemia       Date:  2003-08       Impact factor: 11.528

8.  Guidelines for pediatric cancer centers.

Authors:  James J Corrigan; Stephen A Feig
Journal:  Pediatrics       Date:  2004-06       Impact factor: 7.124

9.  Protocol for the examination of specimens from patients (children and young adults) with rhabdomyosarcoma.

Authors:  Stephen J Qualman; Jay Bowen; David M Parham; Philip A Branton; William H Meyer
Journal:  Arch Pathol Lab Med       Date:  2003-10       Impact factor: 5.534

Review 10.  Establishing a tumour bank: banking, informatics and ethics.

Authors:  S J Qualman; M France; W E Grizzle; V A LiVolsi; C A Moskaluk; N C Ramirez; M K Washington
Journal:  Br J Cancer       Date:  2004-03-22       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.